Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | RPA1 | P27694 | 2/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.41 |
| ▸ | CTRC | Q99895 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13075843 | 0.82 | NTRK1 (0.40) | GABRA2GABRB2EGLN1SMN1; SMN2RPA1 | |
| SCHEMBL3498830 | 0.76 | PTGS1 (0.51) | GABRA2GABRB2MCL1EGLN1SMN1; SMN2 | |
| SCHEMBL3498169 | 0.74 | KMO (0.47) | GABRA2GABRB2MCL1EGLN1SMN1; SMN2 | |
| SCHEMBL3498537 | 0.74 | EGLN1 (0.67) | GABRA2GABRB2EGLN1NPC1RAB9A | |
| SCHEMBL30256794 | 0.73 | RXFP1 (0.42) | MCL1EGLN1SMN1; SMN2KMOMAPT | |
| SCHEMBL21044577 | 0.70 | MCL1 (0.69) | GABRA2GABRB2MCL1SMN1; SMN2RPA1 | |
| SCHEMBL15748871 | 0.69 | RAB9A (0.48) | GABRA2GABRB2EGLN1SMN1; SMN2RPA1 | |
| SCHEMBL3500124 | 0.68 | GRM5 (0.53) | GABRA2GABRB2MCL1EGLN1SMN1; SMN2 | |
| SCHEMBL3497394 | 0.68 | PPP1CA (0.48) | GABRA2GABRB2SMN1; SMN2RPA1KMO | |
| SCHEMBL3498341 | 0.68 | GABRA2 (0.47) | GABRA2GABRB2EGLN1SMN1; SMN2RPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | GABRA2 317/4885GABRB2 169/4885MCL1 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.